Led · Equity · Mar 2026

Founded in 2018, BioInnovation Institute (BII) operates as a non-profit incubator dedicated to translating cutting-edge scientific research into commercially viable companies. Backed by the Novo Nordisk Foundation, the institute offers funding, laboratory facilities and business development assistance to entrepreneurs across healthtech, agritech, climatetech and deeptech. Through programs such as Venture House, BII can provide portfolio companies with up to €1.8 million each, combining initial and follow-on tranches. In its latest allocation, BII distributed €1.3 million in follow-on capital to five startups—Synuca Therapeutics, Gefjon Pharma, MicroMiner, DARERL and Diasense—to advance product development and scaling. The organisation’s broader mandate has been strengthened by a recent commitment of up to €736 million from the Novo Nordisk Foundation, enabling expansion into new strategic areas and geographies. This substantial backing positions BII to support a larger pipeline of European life-science ventures and accelerate their path to market.

Led · Equity · Mar 2026

Founded in 2025 in Aarhus, Denmark, Synuca Therapeutics builds on decades of Aarhus University research in P-type ATPases and neuroscience. The company is engineering small-molecule modulators of the SERCA calcium transporter to restore neuronal calcium balance disrupted by pathological α-Synuclein, aiming to create a first-in-class disease-modifying therapy for Parkinson’s Disease and associated synucleinopathies. Synuca is the inaugural startup supported through BioInnovation Institute’s €42 million innovation partnership with Lundbeckfonden. To date it has obtained €1.8 million in non-dilutive funding from BII, comprising an initial €500 k grant and a new €1.3 million follow-on award. The fresh capital will be used to accelerate lead optimisation, expand mechanistic studies and prepare for pre-clinical development. Participation in BII’s Venture House programme also provides the team with lab space, commercial support and mentorship. The company is still pre-revenue with no clinical trials yet initiated.

Participated · Seed · Feb 2025

Fuse Vectors develops an infinitely scalable, cell-free manufacturing platform for viral vector–based gene therapies, focusing on Adeno-Associated Virus (AAV) vectors. Its enzymatic AAV capsid filling process eliminates cell-based AAV production and uses a module library to store components for on-demand, controlled biocatalytic reactions. The technology is designed to reduce production time and costs while improving vector quality and working across all serotypes. Founded in 2022 and based in Copenhagen, the company is currently in alpha testing and collaborates with more than half a dozen partners, from academic groups to pharmaceutical companies. Fuse plans two commercialisation strategies: partnering with pharmaceutical companies, biotech firms, and academic institutions, while advancing its internal platform and pipeline of novel gene therapies.

Led · Equity · Sep 2023

Founded in 2021, MATR Foods develops clean-label, plant-based meat substitutes by applying traditional fungal fermentation to locally sourced Scandinavian ingredients such as oats, split peas, lupins, beetroots and potatoes. Its flagship product, MATR Fungi Mince, delivers a meat-like amino-acid profile while generating just 1.5 kg CO2e per kilogram—94 % less than beef—without additives or heavy processing. Current listings include Gasoline Grill, Sticks n’ Sushi, Mother Pizza, Sokkelund Brasserie, Meyers canteens, Nemlig.com, Alma and Aarstiderne. The company plans to scale production at its Ansager site to 4,000 tonnes annually, a move expected to create about 60 jobs and serve customers in Denmark, Germany and Switzerland. This expansion will add a new production line targeted to be operational by early 2027. MATR Foods positions itself as both a nutritious and sustainable alternative to conventional meat, aiming to combine deep umami flavour with a markedly lower carbon footprint.

Participated · Equity · Dec 2022

Founded in 2021, EvodiaBio is a Danish industrial biotech company that uses precision-fermentation to produce natural monoterpene aromas with far lower resource use and CO₂ emissions than traditional extraction methods. Its Yops technology platform has already been deployed in more than 70 commercial brews and over 10 projects with top-40 breweries worldwide, and the firm has formed channel partnerships with Symrise and Lallemand. In just three and a half years the team moved from academic research to fully approved industrial production and has launched a profitable product line. Management now plans to accelerate growth in existing markets while expanding into Asia and adjacent sectors such as wine and broader aroma applications. The company reports “profitable from day one” unit economics and rapid commercial traction. To date EvodiaBio has secured €20 million across three funding rounds, including a €7 million raise last year and the latest €6 million round announced today.